Genome-Wide Characterization of Recombinant AAV6 Vector Integration in Human CD34 + Cells
International Journal of Stem Cells · 27.07.2026
DOI: 10.15283/ijsc26038 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Stem Cells, online erschienen am 27.07.2026. Verfasst von Hyeon Jeong Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea. Gefördert von: Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Several viral vectors have been developed for gene therapy due to their high transduction efficiency, but some integrate into the host genome, raising safety concerns.Recent studies have identified recombinant adeno-associated virus serotype 6 (rAAV6) as a promising vector for hematopoietic stem and progenitor cell-targeted gene therapy because of its non-pathogenic nature, low integration frequency, and capacity for sustained episomal transgene expression.Nevertheless, its chromosomal integration profile remains incompletely defined, warranting a comprehensive evaluation to assess long-term safety.In this study, human CD34+ cells were transduced with rAAV6 under varying vector doses and transgene contexts, and integration-site mapping was performed using the integration-site enriched library sequencing approach.Consistent with the largely episomal nature of AAV, high vector sequence alignment rates were observed across all groups.rAAV6 integrations occurred randomly throughout the genome, showing a broad pan-chromosomal distribution without evidence of sequence-specific targeting or clustering.Although integrations were more frequent in CpG islands, commonly located within open chromatin, this pattern likely reflects chromatin accessibility rather than targeting bias.Functional enrichment analysis indicated associations with general cellular and structural processes, without enrichment in oncogenic pathways.Distance-based analysis confirmed that integration sites were mapped at a distance from oncogenes and tumor suppressor genes, even under high-dose conditions.The data support the genomic safety of rAAV6 and its applicability to hematological gene therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea.
- Department of Biomedical Science and Engineering, Konkuk University, Seoul, Korea.
ORCID-Profile: Hyeon Jeong Lee, Nayoung Park, In-Byung Park, Seok-Jin Kang, Joonbeom Bae, Jaebum Kim, Taehoon Chun
Förderung
- Ministry of Food and Drug Safety
Zitieren
APA
Lee, H. J., Park, N., Park, I. B., Kang, S. J., Bae, J., Kim, J., & Chun, T. (2026). Genome-Wide Characterization of Recombinant AAV6 Vector Integration in Human CD34 + Cells. International Journal of Stem Cells. https://doi.org/10.15283/ijsc26038
Vancouver
Lee HJ, Park N, Park IB, Kang SJ, Bae J, Kim J, et al. Genome-Wide Characterization of Recombinant AAV6 Vector Integration in Human CD34 + Cells. International Journal of Stem Cells. 2026. doi:10.15283/ijsc26038
BibTeX
@article{Lee2026,
author = {Lee, Hyeon Jeong and Park, Nayoung and Park, In-Byung and Kang, Seok-Jin and Bae, Joonbeom and Kim, Jaebum and Chun, Taehoon},
title = {Genome-Wide Characterization of Recombinant AAV6 Vector Integration in Human CD34 + Cells},
journal = {International Journal of Stem Cells},
year = {2026},
doi = {10.15283/ijsc26038}
}
EUVIMED